Literature DB >> 18787618

Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease.

Yasuhiro Fujino1, Dennis W Dickson.   

Abstract

Microvacuolation is relatively common in the limbic lobe in Lewy body disease (LBD). Similar pathology has also been reported in Alzheimer's disease (AD). Almost all of the studies of microvacuolation in AD, however, antedated the routine application of sensitive immunohistochemical methods to detect Lewy bodies. This raises the possibility that microvacuolation previously reported in AD may have been due to unrecognized LB pathology. To explore this issue, alpha-synuclein immunohistochemistry was used to evaluate a consecutive series of AD as well as cases with mixed AD and LBD (AD/LBD). Independently, the degree of microvacuolation was graded in the entorhinal cortex and the amygdala of the same cases. The results showed that microvacuolation was more common and more severe in AD/LBD than in pure AD cases. In pure AD cases microvacuolation was related to senile plaque density, especially in the amygdala, where many of the neuropil vacuoles were around dense-cored, neuritic plaques. In contrast, in AD/LBD microvacuolation correlated with LB density in the entorhinal cortex and amygdala. These results suggest that microvacuolation has a different pathogenesis in AD and in AD/LBD. Moreover, when prominent microvacuolation is detected in AD, it is imperative to exclude concurrent LBD.

Entities:  

Keywords:  Alzheimer's disease; Lewy body disease; microvacuolation; spongiosis

Year:  2008        PMID: 18787618      PMCID: PMC2480549     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

Review 1.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

2.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

3.  Diagnostic accuracy of dementia with Lewy bodies.

Authors:  U Hohl; P Tiraboschi; L A Hansen; L J Thal; J Corey-Bloom
Journal:  Arch Neurol       Date:  2000-03

4.  The Lewy body variant of Alzheimer disease.

Authors:  L A Hansen
Journal:  J Neural Transm Suppl       Date:  1997

Review 5.  Frontal lobe degeneration of non-Alzheimer type. Structural characteristics, diagnostic criteria and relation to other frontotemporal dementias.

Authors:  A Brun; U Passant
Journal:  Acta Neurol Scand Suppl       Date:  1996

6.  Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases).

Authors:  H Budka; A Aguzzi; P Brown; J M Brucher; O Bugiani; F Gullotta; M Haltia; J J Hauw; J W Ironside; K Jellinger
Journal:  Brain Pathol       Date:  1995-10       Impact factor: 6.508

7.  Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.

Authors:  A Heyman; G G Fillenbaum; M Gearing; S S Mirra; K A Welsh-Bohmer; B Peterson; C Pieper
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.

Authors:  J M Olichney; D Galasko; D P Salmon; C R Hofstetter; L A Hansen; R Katzman; L J Thal
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

9.  Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease.

Authors:  E Iseki; W Marui; K Kosaka; H Akiyama; K Ueda; T Iwatsubo
Journal:  Neurosci Lett       Date:  1998-12-18       Impact factor: 3.046

10.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

View more
  3 in total

1.  White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging.

Authors:  Zuzana Nedelska; Christopher G Schwarz; Bradley F Boeve; Val J Lowe; Robert I Reid; Scott A Przybelski; Timothy G Lesnick; Jeffrey L Gunter; Matthew L Senjem; Tanis J Ferman; Glenn E Smith; Yonas E Geda; David S Knopman; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2015-03-14       Impact factor: 4.673

2.  Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies.

Authors:  Jagan A Pillai; Guiyun Wu; Babak Tousi; Mykol Larvie; Gabriel C Léger; James B Leverenz
Journal:  Parkinsonism Relat Disord       Date:  2019-03-15       Impact factor: 4.891

3.  Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI.

Authors:  K Kantarci; R Avula; M L Senjem; A R Samikoglu; B Zhang; S D Weigand; S A Przybelski; H A Edmonson; P Vemuri; D S Knopman; T J Ferman; B F Boeve; R C Petersen; C R Jack
Journal:  Neurology       Date:  2010-06-01       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.